A single psilocybin dose shifted self-perception and cut depression scores in 37 patients
Psychedelic research had a busy week — new trial data, a neuroscience deep-dive, and one very alarming mushroom.
Here's what the evidence actually showed.
🍄 One Dose, Two Weeks, a Different Sense of Self
- In a randomized, double-blind trial of 37 people with major depressive disorder, a single moderate psilocybin dose produced significant reductions in depressive symptoms and a measurable increase in positive self-concept within two weeks — compared to placebo.
- The self-concept shift wasn't decorative: it correlated directly with how much depression scores dropped, suggesting the two are meaningfully linked rather than coincidental.
- Brain imaging added a specific wrinkle: psilocybin changed how the caudate — a region tied to attention and reward — activated during self-referential thinking, while placebo produced the opposite pattern.
Why it matters: This is one of the cleaner controlled datasets connecting psilocybin's psychological effects (how you think about yourself) to its clinical effects (how depressed you feel), with a neural mechanism to interrogate further.
Key Findings
🍄☠️ The Mushroom That's Both Magic and Deadly
- Researchers identified Galerina indica — dubbed the "dark magic mushroom" — as the first known fungal species to produce both psilocybin and amatoxins, the compounds responsible for deadly poisonings.
- Genomic analysis suggests psilocybin biosynthesis arrived via horizontal gene transfer, essentially bolted onto a species that already made lethal toxins. The ecological implications of that combination are unresolved.
🧠 LSD Pushes Gene Expression Away from Brain Aging Patterns
- Transcriptomic analyses across rats and mice showed that LSD treatment produced gene expression profiles strongly anti-correlated with aging-associated changes in the human prefrontal cortex — and the pattern held across multiple doses and datasets.
- In lab-grown cortical cells, short-term LSD treatment also reduced structural and molecular changes triggered by amyloid-beta, the protein fragment implicated in Alzheimer's disease.
💊 Ibogaine's Benefits in Veterans Held at 12 Months
- In 25 male Special Operations veterans with traumatic brain injury histories, improvements in disability, PTSD, depression, and anxiety observed after a single magnesium-ibogaine treatment remained large and statistically robust through 12 months.
- Caveat worth noting: most participants used other psychedelic substances or pursued additional interventions during follow-up, making ibogaine's standalone contribution difficult to isolate.
🔗 Feeling Connected May Explain Psilocybin Retreat Benefits
- A prospective naturalistic study found that increased sense of connectedness — to others, nature, or something larger — emerged as a candidate pathway linking psilocybin retreat experiences to sustained improvements in wellbeing outside clinical settings.
- The finding matters for public mental health framing: it suggests retreats may work partly through social and relational mechanisms, not just pharmacology.
💉 Ketamine Rewires Serotonin Circuits in Circuit-Specific Ways
- Animal research showed ketamine increased the firing of serotonin-producing neurons in the dorsal raphe while simultaneously strengthening some glutamate inputs and weakening others — depending on where those neurons projected in the brain.
- The synaptic strengthening toward the prefrontal cortex required a growth-factor receptor signal; the firing-rate increase did not. Two parallel pathways, not one.
💻 Ketamine Clinic Websites in South Florida Raised Safety Transparency Concerns
- A cross-sectional audit of ketamine clinic websites in South Florida found that direct-to-consumer information was subject to limited oversight, with incomplete or potentially misleading disclosures about safety risks and regulatory status.
- As clinics expand rapidly across the U.S., the gap between what patients read online and what they need to make informed decisions represents a concrete, underaddressed problem.
Implications
Psilocybin, ketamine, ibogaine, and LSD each showed distinct but converging signals this week — from self-concept shifts to gene expression patterns to year-long symptom relief. The unresolved tension: most of these findings are small, unblinded, or animal-based, and the field still lacks consensus on which mechanisms actually drive durable human outcomes.
Studies in this issue
Primary sources used for this newsletter.
- Changes in self-thinking and depression severity after one moderate dose of psilocybin in depressed patientsmain storyPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2026-11-10PMID 43007824
- The 'dark magic mushroom' produces both poisonous amatoxins and psychedelic psilocybinkey findingCurrent biology : CB2026-11-11PMID 43014316
- Ketamine's selective effects on serotonin-making cells in a brain area controlling moodkey findingiScience2026-11-12PMID 43017108
- Feeling connected may link experiences at psilocybin retreats to lasting wellbeingkey findingFrontiers in psychiatry2026-11-12PMID 43016926
- Patient Safety and Regulation Information on Ketamine Clinic Websites in South Floridakey findingJournal of psychiatric practice2026-11-11PMID 43013865
- LSD causes gene activity changes that counter brain aging and nerve cell damagekey findingAging cell2026-11-10PMID 43009443
- Long-term effects of magnesium-ibogaine treatment in special operations veterans with traumatic brain injurieskey findingTranslational psychiatry2026-11-09PMID 43003815
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.